EP Patent

EP2968344A1 — Use of linagliptin in cardio- and renoprotective antidiabetic therapy

Assigned to Boehringer Ingelheim International GmbH · Expires 2016-01-20 · 10y expired

What this patent protects

The present invention relates to the DPP-4 inhibitor linagliptin for use in cardio- and/or renoprotective therapy, including in diabetic or non- diabetic patients at high vascular risk.

USPTO Abstract

The present invention relates to the DPP-4 inhibitor linagliptin for use in cardio- and/or renoprotective therapy, including in diabetic or non- diabetic patients at high vascular risk.

Drugs covered by this patent

Patent Metadata

Patent number
EP2968344A1
Jurisdiction
EP
Classification
—
Expires
2016-01-20
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.